All In Biotech

Drug Trial Radar · NCT07290777

VEL-101 to Prevent Rejection After Kidney Transplantation

A Phase 2, Randomized, Partially Blinded, Controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VEL-101 in Kidney Transplant Recipients.

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Asahi Kasei Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.

Conditions

  • Transplantation, Kidney

Interventions

  • Tacrolimus (TAC)Drug

    Tacrolimus Immediate Release in addition to SOC

  • VEL-101Drug

    VEL-101 in addition to SOC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of serious adverse events (SAEs)Time frame: Month 12
  2. Incidence of treatment emergent adverse events (TEAEs)Time frame: Month 12
  3. PK Parameter CmaxTime frame: Day 1, Month 3
  4. PK Parameter CminTime frame: Day 1, Month 3
  5. PK Parameter TmaxTime frame: Day 1, Month 3
  6. AUC from 0-8 hoursTime frame: Day 1, Month 3
  7. AUC from 0 to 48 hoursTime frame: Day 2
  8. VEL-101 Accumulation RatioTime frame: Month 3
  9. VEL-101 Pre-Dose Serum ConcentrationTime frame: Day 1, Day 14, Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biospy)
  10. Effect of Anti-Drug Antibody (ADA) Development on VEL-101 Serum ConcentrationTime frame: Months 1, 2, 3, 6, 9, 12, Periprocedural (kidney biopsy)
  11. Effect of Neutralizing Antibody (NAb) Development on VEL-101 Serum ConcentrationTime frame: Day 1, Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)
  12. VEL-101 CD28 Receptor Occupancy Concentration (%)Time frame: Days 1, 2, 3, 4, 5, 7, 14, 42, 70, 82, 91, 98 and Months 1, 2, 3, 6, 9, 12 and Periprocedural (kidney biopsy)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • USA Site #1087

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.